{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:20:47Z","timestamp":1788675647587,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Staidson (Beijing) Biopharmaceuticals","award":["\/"],"award-info":[{"award-number":["\/"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40121-023-00759-4","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T13:03:20Z","timestamp":1674651800000},"page":"663-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults"],"prefix":"10.1007","volume":"12","author":[{"given":"Guiling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiahong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conggao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"16","key":"759_CR1","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2020.5394","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region. Italy Jama. 2020;323(16):1574\u201381.","journal-title":"Italy Jama."},{"issue":"14","key":"759_CR2","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/bph.15187","volume":"178","author":"S Jodele","year":"2021","unstructured":"Jodele S, K\u00f6hl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2021;178(14):2832\u201348.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"759_CR3","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jaip.2020.04.014","volume":"8","author":"B Lipworth","year":"2020","unstructured":"Lipworth B, Chan R, Lipworth S, RuiWen KC. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J Allergy Clin Immunol Pract. 2020;8(6):1798\u2013801.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"759_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","volume":"22","author":"B Afzali","year":"2022","unstructured":"Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77\u201384.","journal-title":"Nat Rev Immunol"},{"key":"759_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1\u201313.","journal-title":"Transl Res"},{"issue":"2","key":"759_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"759_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","volume":"146","author":"M Cugno","year":"2020","unstructured":"Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"759_CR8","doi-asserted-by":"crossref","unstructured":"Gralinski LE, Sheahan TP, Morrison TE, et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018;9(5).","DOI":"10.1128\/mBio.01753-18"},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2017.05.019","volume":"89","author":"Y Laumonnier","year":"2017","unstructured":"Laumonnier Y, Karsten CM, K\u00f6hl J. Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol. 2017;89:44\u201358.","journal-title":"Mol Immunol"},{"issue":"8","key":"759_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood.V76.8.1631.1631","volume":"76","author":"R Schindler","year":"1990","unstructured":"Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood. 1990;76(8):1631\u20138.","journal-title":"Blood"},{"issue":"8","key":"759_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","volume":"114","author":"SV Seshan","year":"2009","unstructured":"Seshan SV, Franzke CW, Redecha P, Monestier M, Mackman N, Girardi G. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood. 2009;114(8):1675\u201383.","journal-title":"Blood"},{"issue":"7","key":"759_CR12","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","volume":"177","author":"K Ritis","year":"2006","unstructured":"Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794\u2013802.","journal-title":"J Immunol"},{"issue":"5","key":"759_CR13","volume":"4","author":"R Wang","year":"2015","unstructured":"Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015;4(5): e28.","journal-title":"Emerg Microbes Infect."},{"key":"759_CR14","doi-asserted-by":"crossref","unstructured":"Jiang Y, Li J, Teng Y, et al. Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses. 2019;11(1).","DOI":"10.3390\/v11010039"},{"issue":"1","key":"759_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","volume":"7","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhao G, Song N, et al. Blockade of the C5a\u2013C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77.","journal-title":"Emerg Microbes Infect."},{"issue":"10","key":"759_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164646","volume":"11","author":"P Bekker","year":"2016","unstructured":"Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS ONE. 2016;11(10): e0164646.","journal-title":"PLoS ONE"},{"issue":"7","key":"759_CR17","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"759_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Fukuda T, Mizuno K, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22(2):307\u201315.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"759_CR19","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","volume":"2","author":"APJ Vlaar","year":"2020","unstructured":"Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2(12):e764\u201373.","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"759_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/cts.13213","volume":"15","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar APJ, Lim EHT, de Bruin S, et al. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci. 2022;15(4):854\u20138.","journal-title":"Clin Transl Sci"},{"issue":"11","key":"759_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000577","volume":"3","author":"M Bauer","year":"2021","unstructured":"Bauer M, Weyland A, Marx G, et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal Anti-C5a antibody, in patients with early severe sepsis or septic shock-a randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS study). Crit Care Explor. 2021;3(11): e0577.","journal-title":"Crit Care Explor."},{"key":"759_CR22","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. E Clin Med. 2020;28: 100590.","journal-title":"E Clin Med."},{"issue":"4","key":"759_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/cid\/ciu887","volume":"60","author":"S Sun","year":"2015","unstructured":"Sun S, Zhao G, Liu C, et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015;60(4):586\u201395.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"759_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(12):1137\u201346.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"759_CR25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S0022-5223(98)70059-5","volume":"116","author":"M Tofukuji","year":"1998","unstructured":"Tofukuji M, Stahl GL, Agah A, Metais C, Simons M, Sellke FW. Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg. 1998;116(6):1060\u20138.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"759_CR26","doi-asserted-by":"publisher","first-page":"7902","DOI":"10.4049\/jimmunol.178.12.7902","volume":"178","author":"LM Hoesel","year":"2007","unstructured":"Hoesel LM, Niederbichler AD, Schaefer J, et al. C5a-blockade improves burn-induced cardiac dysfunction. J Immunol. 2007;178(12):7902\u201310.","journal-title":"J Immunol"},{"issue":"5","key":"759_CR27","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1097\/CCM.0000000000002950","volume":"46","author":"S Sun","year":"2018","unstructured":"Sun S, Jiang Y, Wang R, et al. Treatment of paraquat-induced lung injury with an Anti-C5a antibody: potential clinical application. Crit Care Med. 2018;46(5):e419\u201325.","journal-title":"Crit Care Med"},{"issue":"1","key":"759_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/157489106775244091","volume":"1","author":"RF Guo","year":"2006","unstructured":"Guo RF, Ward PA. C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov. 2006;1(1):57\u201365.","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"7","key":"759_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","volume":"7","author":"D Ajona","year":"2017","unstructured":"Ajona D, Ortiz-Espinosa S, Moreno H, et al. A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 2017;7(7):694\u2013703.","journal-title":"Cancer Discov"},{"issue":"2","key":"759_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428\u201355.","journal-title":"Allergy"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00759-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T22:18:45Z","timestamp":1676326725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00759-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00759-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}